Similar documents
Behavioral Pharmacology

A Handbook on Drug and Alcohol Abuse

Neurobiology of Drug Abuse and Addiction PSYC 450

Preclinical Abuse Liability Screening: Using The CSS-PhRMA Dialogue Sessions as a Model. David V. Gauvin, Ph.D. MPI Research, Inc.

GABA A receptors and therapeutics: beyond benzodiazepines

Unit II Problem 7 Pharmacology: Substance Abuse, Dependence and Addiction

MOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre

Preclinical Psychopharmacology: From Mechanisms & Molecules to Medicines

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

America is a drugged society

At a Glance. Background Information. Lesson 3 Drugs Change the Way Neurons Communicate


A substance that reduces pain and may or may not have psychoactive properties.

Washtenaw Community College Comprehensive Report. PSY 296 Neuropsychology of Addiction Effective Term: Winter 2019

CHD 110 PSYCHOPHARMACOLOGY AND SUBSTANCE ABUSE

BEHAVIOURAL SCREENING OF DRUGS HYPNOTICS/SEDATIVES

Research Priorities of NIDA s Medications Development Program

The Science of Addiction: Genetics and the Brain Webquest

The Science of Addiction Webquest

Food restriction: enhancing effects on drug reward and striatal cell signaling

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

Understanding Addiction and Dugs Of Abuse

^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs

Substance Abuse and Addictions Substance abuse: a pattern of substance use that produces clinically significant impairment or distress.

Alcohol: Its effects on the brain and implications for future treatment. Dr Mark Daglish

The future of pharmacological treatment.

NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1

DRUGS AND SOCIETY. Behavioral Medicines and Abusabie Drugs. Arthur P. Leccese, Ph.D. Kenyon College. PRENTICE HALL, Englewood Cliffs, New Jersey 07632

Low Dopamine Receptor Availability May Promote Cocaine Addiction

Ideal Sedative Agent. Benzodiazepines 11/12/2013. Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry.

Assessing the Clinical Abuse Potential of Abuse Deterrent Opioid Formulations

Prescription Drug Abuse: Prevention and Treatment Across the Continuum of Care

Ideal Sedative Agent. Pharmacokinetics. Benzodiazepines. Pharmacodynamics 11/11/2013

Effects of a Novel Fentanyl Derivative on Drug Discrimination and Learning in Rhesus Monkeys

Identifying Key Characteristics and Habits of the Recreational Drug User

Fundamentals of Psychopharmacology. Distribution of Receptors Influences Safety

Discriminative Stimulus Effects of a Cocaine/Heroin Speedball Combination in Rhesus Monkeys 1

Drugs, The Brain, and Behavior

Understanding Alcohol And Other Drugs Of Abuse

Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America

Guidance for Industry

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances

Pharmacology of Addic0ve Disorders

The Biological Perspective. Jørg Mørland Senior researcher, Norwegian Institute of Public Health Professor em of Medicine University of Oslo

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Polysubstance Use & Medication-Assisted Treatment

BRAIN MECHANISMS OF REWARD AND ADDICTION

Potential for delta opioid receptor agonists as analgesics in chronic pain therapy

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Physical and Physiological Aspects of Drug Use and Abuse

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Psychoactive drugs Drugs which affect mental processes. Legal but restricted (by prescription only)

EDUCATIONAL COMMENTARY METHADONE

Fentanyls and Naloxone. Opioids, Overdose, and Naloxone

Brain, Pain, Opioids. John Hart, DO

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO

Table of Contents VOLUME 1

The Neurobiology of Drug Addiction

Addiction in the Brain - Latest Research. Gary M. Henschen, MD, LFAPA Chief Behavioral Health Officer Magellan Healthcare, Inc.

25/03/2014. Workshop Overview. Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care:

Understanding the Brain: What Drugs Can Tell Us

Explaining the Escalation of Drug Use in Substance Dependence: Models and Appropriate Animal Laboratory Tests

BENZODIAZEPINE DEPENDENCE AMONG MULTIDRUG USERS IN THE CLUB SCENE. Steven P. Kurtz and Mance E. Buttram


A handful of dangerous new legal drugs has public health experts worried

Psychoactive Drugs & The Brain

Cocaine-Like Discriminative Stimulus Effects of Heroin: Modulation by Selective

Qualifying Examination (Part I)

NEUROBIOLOGY ALCOHOLISM

SECTION 1 LEARNING OBJECTIVES:

Cocaine-Like Discriminative Stimulus Effects of Heroin: Modulation by Selective Monoamine Transport Inhibitors

5.2 Altering Consciousness With Psychoactive Drugs LEARNING OBJECTIVES

The Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

Alcoholism And Addiction In The Elderly

Neurobiology of Addiction and Recovery

Neuropsychiatry. I. Schizophrenia II. Mood Disorders III. Substance-Related Disorders

ECHO Presentation Addiction & Brain Function

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?

Neurobiology of Addiction and Recovery. R. Dewayne Book, M.D. Medical Director Fellowship Hall Greensboro, North Carolina

FDA Expectations and Evaluation of Inhalation Toxicology Studies

Psychopharmacology 9 Springer-Verlag 1982

Selectivity in the Generalization Profile in Baboons Trained to Discriminate Lorazepam: Benzodiazepines, Barbiturates and Other Sedative/Anxiolytics 1

Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

Howard Abadinsky. St. John's University THOMSON + WADSWORTH. Australia Canada Mexico Singapore Spain United Kingdon United States

PRACTICE ALERT. New ICD Code Changes. Mirean Coleman, LICSW, CT Clinical Manager. December 2017

by popular demand: Addiction II

ES.S10: Drugs and the Brain Syllabus Spring 2013 Zak Fallows

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

Learning theory provides the basis for behavioral interventions. The USMLE behavioral science section always contains questions relating to learning

DANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR

General introduction. Chapter 1

The Drug Testing Process. Employer or Practice

Action Potentials and Synaptic Transmission. BIO 219 Napa Valley College Dr. Adam Ross

THE STATE OF MEDICINE IN ADDICTION RECOVERY

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

PK/PD analysis in assessment of abuse deterrence

The study of drugs. Pharmacology

Understanding Drug and Alcohol Abuse and Addiction

Transcription:

No!

No!

No!

No! With the possible exception of humans

Public Health Question Does the compound have the potential to be abused?

Public Health Question Does the compound have the potential to be abused? Preclinical Laboratory Questions Equivalent to reference compound (drug of abuse)? Positive reinforcing effects? Physical dependence (tolerance)?

Primary Data on Abuse Potential a. Chemistry b. Preclinical pharmacology c. Animal behavioral and dependence pharmacology d. Pharmacokinetics/pharmacodynamics e. Human abuse potential laboratory studies f. Clinical trial data relative to abuse and dependence potential g. Integrated summaries of safety and efficacy h. Foreign experience with the drug (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Types of Preclinical Studies 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Types of Preclinical Studies 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Types of Preclinical Studies 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Types of Preclinical Studies 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Types of Preclinical Studies 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Equivalence to reference compound(s)? Antinociception Anticonvulsant Learning and memory Food intake Locomotion Similarities/differences do not provide insight on mechanism or abuse liability

Relevance of Locomotion Dopamine systems mediate locomotor activation Some drugs of abuse Some drugs of abuse dopamine neurotransmission locomotion Other drugs of abuse locomotion

Drug that locomotion might be a stimulant (e.g. cocaine) Drug that locomotion might be a sedative (e.g. benzodiazepine)

Limitations of Locomotion All drugs locomotion Non-abused drugs locomotion Insensitive to important factors (pharmacokinetics) Challenging to study in some species (primates)

Variations on Locomotion Sensitization to locomotor effects

Variations on Locomotion Sensitization to locomotor effects -increased response over repeated testing -cross sensitization among some drugs of abuse - neuroplasticity is hallmark of abuse?

1

1 2

3 2 1

4 3 2 1

Variations on Locomotion Sensitization to locomotor effects Lack of covariance Occurs with non-abused drugs Evident only under selected conditions Relationship to reinforcing effects? Relevance to substance abuse?

No, but it is useful!

Types of Animal Studies (FDA) 1. Self administration ( if animals work to receive drug likely the drug is rewarding in humans. ) 2. Conditioned place preference ( not as rigorous a test as self administration ) 3. Drug discrimination ( produces perceptions similar to a drug of abuse. ) 4. Psychomotor tests ( comparison with drugs of abuse ) 5. Dependence potential ( give rise to need for repeated doses often characterized by withdrawal ) (FDA Guidance for Industry, Assessment of Abuse Potential of Drugs, January 2010)

Drug Discrimination: Methodology Subjective effects in humans Drug discrimination in non-humans

Drug Discrimination: Methodology Heroin versus saline discrimination HEROIN FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination HEROIN FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination HEROIN SALINE FOOD FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination HEROIN SALINE FOOD FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination HEROIN SALINE FOOD FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination TEST HEROIN? SALINE? FOOD FOOD

Drug Discrimination: Methodology Heroin versus saline discrimination in rats % Heroin Lever Responding 100 90 80 70 60 50 40 30 20 10 0 Rat Saline Heroin

Drug Discrimination: Methodology Heroin versus saline discrimination in rats Morphine substitution % Heroin Lever Responding 100 90 80 70 60 50 40 30 20 10 0 Rat Saline Heroin Morphine

Drug Discrimination: Methodology Heroin versus saline discrimination in rats Morphine substitution Pharmacological specificity - cocaine % Heroin Lever Responding 100 90 80 70 60 50 40 30 20 10 0 Rat Saline Heroin Cocaine

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Midazolam - - + Pentobarbital - - +

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Midazolam - - + Pentobarbital - - +

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Midazolam - - + Pentobarbital - - +

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Midazolam - - + Pentobarbital - - + TEST SUBSTANCE???

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Cocaine-like stimulant (dopamine) Midazolam - - + Pentobarbital - - + TEST SUBSTANCE + - -

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Heroin-like (µ) opioid Midazolam - - + Pentobarbital - - + TEST SUBSTANCE - + -

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + - Midazolam-like sedative/hypnotic (GABA A ) Midazolam - - + Pentobarbital - - + TEST SUBSTANCE - - +

Drug Discrimination Strengths Pharmacologic specificity TRAINING DRUG TEST DRUG Cocaine Heroin Midazolam ----------------------------------------------------------------------------------------- Cocaine + - - Amphetamine + - - Heroin - + - Morphine - + -? Midazolam - - + Pentobarbital - - + Phencyclidine - - -

Question Determines the Answer Which comparison(s)? Cocaine/amphetamine (dopamine, DAT) Heroin (opioid) Benzodiazepine (GABA) Phencyclidine (NMDA) LSD (5-HT) THC (CB 1 )....

Drug Discrimination Strengths Pharmacologic specificity (pharmacodynamics) Consistent across species Stable baseline Relatively insensitive to pharmacokinetics

Drug Discrimination Limitations Not necessarily related to abuse liability Discrimination on non-abused drugs

Drug Discrimination Limitations Discrimination of nonabused drugs % U50488 Lever Responding 100 90 80 70 60 50 40 30 20 10 0 Rhesus monkey Saline U50488 Morphine

Drug Discrimination Limitations Not necessarily related to abuse liability Discrimination on non-abused drugs PK factors relatively unimportant for discrimination

Drug Discrimination Limitations Not necessarily related to abuse liability Discrimination on non-abused drugs PK factors relatively unimportant for discrimination Constraints of high pharmacological specificity Multiple mechanisms can mask relevant signal

Drug Discrimination: Masking Stimuli TRAINING SUBSTANCE cocaine Mechanism A DAT Mechanism B Mechanism C TEST SUBSTANCE

% Morphine-lever responding 100 80 60 40 20 0 Control 1.0 THC Control V 0.32 1 3.2 10 Dose (mg/kg) morphine

% Morphine-lever responding 100 80 60 40 20 0 Control 1.0 THC Control + 1 mg/kg Δ 9 THC V 0.32 1 3.2 10 Dose (mg/kg) morphine

% Morphine-lever responding 100 80 60 40 20 0 Control 1.0 THC Control + 1 mg/kg Δ 9 THC V 0.32 1 3.2 10 Dose (mg/kg) morphine 17856 17857 AC2P M139 % Morphine-lever responding 100 80 60 40 20 0 0.32 1 3.2 10 0.32 1 3.2 10 0.32 1 3.2 10 0.32 1 3.2 10 Dose (mg/kg) morphine

Drug Discrimination Limitations Not necessarily related to abuse liability PK factors relatively unimportant for discrimination Constraints of high pharmacological specificity Multiple mechanisms can mask relevant signal Novel mechanisms and false negatives

cocaine trained midazolam trained heroin trained nicotine trained alcohol trained phencyclidine trained

cocaine trained midazolam trained - - - heroin trained TEST SUBSTANCE nicotine trained - - - alcohol trained phencyclidine trained

cocaine trained midazolam trained - - - heroin trained Δ 9 THC nicotine trained - - - alcohol trained phencyclidine trained

cocaine trained midazolam trained - - - heroin trained Novel Compound nicotine trained - - - alcohol trained phencyclidine trained

Question Determines the Answer Train discrimination with novel compound Stimulus control confirms activity (likely in brain) Lack of stimulus control does not prove lack of activity/abuse

Question Determines the Answer Train discrimination with novel compound Stimulus control confirms activity (likely in brain) Lack of stimulus control does not prove lack of activity/abuse Test known drugs of abuse Cocaine Heroin Midazolam Phencyclidine Nicotine Δ 9 THC

NOVEL SUBSTANCE TRAINED

cocaine test - NOVEL SUBSTANCE TRAINED

cocaine test - - heroin test NOVEL SUBSTANCE TRAINED

cocaine test - - heroin test NOVEL SUBSTANCE TRAINED - alcohol test

cocaine test - - heroin test NOVEL SUBSTANCE TRAINED - - alcohol test phencyclidine test

cocaine test - - heroin test nicotine test - NOVEL SUBSTANCE TRAINED - - alcohol test phencyclidine test

cocaine test midazolam test - - - heroin test nicotine test - NOVEL SUBSTANCE TRAINED - - alcohol test phencyclidine test

cocaine test midazolam test nicotine test NOVEL SUBSTANCE TRAINED? heroin test alcohol test phencyclidine test

cocaine test midazolam test heroin test GHB nicotine test alcohol test phencyclidine test

cocaine test midazolam test heroin test GHB GABA B baclofen test nicotine test alcohol test phencyclidine test

Question Determines the Answer Train discrimination with novel compound Stimulus control confirms activity (likely in brain) Lack of stimulus control does not prove lack of activity/abuse Test known drugs of abuse Cocaine Heroin Midazolam Phencyclidine Nicotine Δ 9 THC Relationship to abuse?

Question Determines the Answer Train discrimination with novel compound Stimulus control confirms activity (likely in brain) Lack of stimulus control does not prove lack of activity/abuse Test known drugs of abuse Cocaine Heroin Midazolam Phencyclidine Nicotine Δ 9 THC Relationship to abuse? Positive result = implicates specific mechanism of action

Question Determines the Answer Train discrimination with novel compound Stimulus control confirms activity (likely in brain) Lack of stimulus control does not prove lack of activity/abuse Test known drugs of abuse Cocaine Heroin Midazolam Phencyclidine Nicotine Δ 9 THC Relationship to abuse? Positive result = implicates specific mechanism of action Negative result = can exclude specific mechanism(s) of action but does not exclude abuse potential

Lack of discrimination does not exclude abuse Discrimination does not predict abuse Value is identification/confirmation of mechanism

Summary and Conclusion Objectives are to test for equivalence, positive reinforcing effects, and dependence Locomotor behavior and drug discrimination test for equivalence in a very general and a very specific manner, respectively A compliment of procedures in multiple species increases the likelihood of accurate assessment

Species: Which One? Rats Studies in drug-naïve subjects Control drug/behavioral history Drug discrimination with test substance Initiation of self administration with test substance Cost Less compound needed Between-subjects design (>n) Same as other preclinical work (biochemical)

Species: Which One? Mice Studies in drug-naïve subjects Cost Still less compound needed Genetically-modified animals available but very challenging Procedures not well developed or validated

Species: Which One? Non-human primates Preferred by some Phylogenic closeness to humans PK most likely to match human Long-term preparation Within-subjects design PK and behavior in same individual Dose-response in same individual Within-subjects = small group number Drug history might be better model of human abusers Long training Complex tasks Chronic dosing in developmentally stable subject Need more compound Extensive comparative literature

What Dose(s) & Dosing? Range of doses increases predictive value Abusers do not attend to recommended dose Multiples of therapeutic dose Dose selection Behaviorally active dose (operant responding) Based on other data/measures Behavior (therapeutic target) Biochemical/physiological target Blood concentration Relationship to binding in vitro Imaging and receptor/transporter occupancy Route of administration Multiple routes recommended Clinical and another (i.v.) Confirm exposure in behavioral study with PK study Directly study metabolites? Formulations for risk reduction

Disclosure Grant support: National Institutes of Health Contract support: Merz Pharma, Shire, Porsolt Consultant: Porsolt Inc., USA